References
- Sehn L H, Chhanabhai M, Fitzgerald C, Giu K, Hoskins P, Klasa R, et al. Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the Standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP) [abstract]. Blood 2005; 106: 492
- Ganjoo K N, An C S, Robertson M J, Gordon L I, Sen J A, Weisenbach J, et al. Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006; 47: 998–1005
- Midgley R, Kerr D. Bevacizumab – current status and future directions. Ann Oncol 2005; 16: 999–1004
- Salmon J S, Lockhart A C, Berlin J. Anti-angiogenic treatment of gastrointestinal malignancies. Cancer Invest 2005; 23: 712–726
- Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999; 17: 1244–1253